{"id":391217,"date":"2015-12-08T00:00:00","date_gmt":"2015-12-08T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pcorid0115-biopharma-hepatitis-c-virus-pharmacor-g7-2015\/"},"modified":"2026-03-31T09:02:39","modified_gmt":"2026-03-31T09:02:39","slug":"pcorid0115-biopharma-hepatitis-c-virus-pharmacor-g7-2015","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pcorid0115-biopharma-hepatitis-c-virus-pharmacor-g7-2015\/","title":{"rendered":"Hepatitis C Virus | Pharmacor | G7 | 2015"},"content":{"rendered":"<p><em>Last Updated 8 December 2015 <\/em><br \/>\nThe hepatitis C virus (HCV) therapy market is undergoing unprecedented growth. Commercial opportunity is driven by a large prevalent population and historically high unmet medical need due to the suboptimal efficacy and tolerability of interferon-based therapies. Between 2013 and 2015, several direct-acting antivirals (DAAs) and DAA combinations, including simeprevir (Janssen\u2019s Olysio, Medivir\u2019s Sovriad), sofosbuvir (Gilead\u2019s Sovaldi), sofosbuvir\/ledipasvir (Gilead\u2019s Harvoni), ombitasvir\/paritaprevir\/ritonavir plus dasabuvir (AbbVie\u2019s Viekira Pak), and daclatasvir (Bristol-Myers Squibb\u2019s Daklinza), have launched in the G7 for both treatment-naive and -experienced HCV patients. Despite these agents\u2019 high prices, they have become a new standard of care.<\/p>\n","protected":false},"template":"","class_list":["post-391217","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hepatitis-c-virus","biopharma-geography-us","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391217","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391217\/revisions"}],"predecessor-version":[{"id":394340,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391217\/revisions\/394340"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391217"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}